GLUE
HealthcareMonte Rosa Therapeutics, Inc. · Biotechnology · $1B
What is Monte Rosa Therapeutics, Inc.?
Monte Rosa Therapeutics is a clinical-stage biopharmaceutical company focused on molecular glue degrader medicines. Based in Boston and incorporated in 2019, it targets proteins that drive cancer and inflammatory disease by harnessing the body's own protein-disposal machinery.
Monte Rosa develops oral small-molecule drugs called molecular glue degraders, which direct the body's natural protein-degradation system to eliminate disease-causing proteins. Its lead program targets GSPT1 in Myc-driven cancers. Additional pipeline candidates address CDK2 in gynecologic and breast cancers, NEK7 in inflammatory and metabolic diseases, VAV1 in autoimmune conditions, and BCL11A in blood disorders. The company does not yet generate product revenue and funds operations through capital markets.
Monte Rosa Therapeutics was incorporated in 2019 and is headquartered in Boston, Massachusetts.
- GSPT1 molecular glue degrader for Myc-driven cancers
- CDK2 degrader program for ovarian, uterine, and breast cancers
- NEK7 program targeting Crohn's disease and metabolic disorders
- VAV1 program for autoimmune disease
- BCL11A program for hemoglobinopathies
Is GLUE a Good Stock to Buy?
UQS Score rates GLUE as Poor overall, reflecting the early-stage nature and financial profile typical of pre-revenue clinical biotechs.
The Growth and Risk pillars both land at Neutral, suggesting the pipeline's potential is acknowledged while near-term operational risk is neither extreme nor negligible relative to peers. The molecular glue degrader platform addresses genuinely underserved oncology and inflammatory disease indications.
Quality and Moat both register as Weak — consistent with a company that has no commercial products, no recurring revenue, and a competitive landscape where platform differentiation is still being proven. Valuation is rated Elevated, meaning the current market price already prices in considerable future success.
Pro members can see the exact pillar breakdown and full financial metrics behind the GLUE UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does GLUE pay dividends?
No — Monte Rosa Therapeutics, Inc. does not currently pay a dividend.
Monte Rosa Therapeutics does not pay a dividend. As a pre-revenue clinical-stage company, available capital is directed entirely toward research, clinical trials, and pipeline advancement. Income-focused investors should note that a dividend is unlikely until the company reaches commercial-stage profitability, which remains a longer-term prospect.
When does GLUE report earnings?
Monte Rosa Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
Quarterly reports for pre-revenue biotechs like Monte Rosa center on cash runway, operating expenses, and clinical milestone updates rather than sales or profit trends. Pipeline progress and financing activities tend to be the most market-moving disclosures.
For the most recent quarter's results and upcoming reporting dates, visit Monte Rosa Therapeutics' investor relations page directly.
GLUE Price History
-8.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Monte Rosa Therapeutics, Inc.?
Based on Monte Rosa Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
GLUE Long-term Outlook
With Growth rated Neutral and Risk also Neutral, Monte Rosa's near-term trajectory hinges on clinical readouts rather than revenue inflection. The pipeline spans multiple disease areas, which broadens optionality but also spreads resources. An Elevated Valuation rating suggests the market has already priced in meaningful pipeline success, leaving limited margin for setbacks.
Growth drivers
- Advancement of the GSPT1 program through clinical milestones in Myc-driven cancers
- Expansion of the molecular glue degrader platform into additional oncology and inflammatory targets
- Potential partnership or licensing deals that validate the platform and extend cash runway
Key risks
- Clinical trial failure or delays across any of the pipeline programs
- Elevated valuation leaves little buffer if data disappoints or timelines slip
- Ongoing need for external capital in the absence of product revenue
GLUE vs Peers
Monte Rosa operates in a competitive small-cap biotech space alongside other clinical-stage companies pursuing novel oncology and immunology mechanisms.
Inhibrx focuses on engineered protein therapeutics across oncology and rare disease, using a distinct protein-engineering platform rather than small-molecule degraders.
Iovance pursues tumor-infiltrating lymphocyte cell therapies for solid tumors, representing a cell-therapy approach that contrasts with Monte Rosa's oral small-molecule strategy.
ArriVent concentrates on targeted therapies for thoracic cancers, with a pipeline built around specific driver mutations rather than a broad protein-degradation platform.
Frequently Asked Questions
What does Monte Rosa Therapeutics do?
Monte Rosa Therapeutics develops oral molecular glue degrader medicines that use the body's own protein-disposal system to eliminate proteins that drive cancer and inflammatory disease. Its pipeline spans oncology targets like GSPT1 and CDK2, as well as inflammatory and autoimmune programs including NEK7 and VAV1.
Does GLUE pay dividends?
No. Monte Rosa Therapeutics does not pay a dividend. The company is pre-revenue and directs all available capital toward clinical development. A dividend is not expected until the company reaches sustained commercial profitability.
When does GLUE report earnings?
Monte Rosa reports on a standard quarterly cadence. Because our data source does not carry forward-looking earnings dates, check the company's investor relations page for the most current schedule and recent filings.
Is GLUE a good stock to buy?
The UQS Score rates GLUE as Poor overall, driven by Weak Quality and Moat scores alongside an Elevated Valuation. That profile reflects the high uncertainty inherent in pre-revenue clinical-stage biotechs. The complete pillar breakdown is available to Pro members on UQS Score.
Is GLUE overvalued?
The UQS Valuation pillar for GLUE is rated Elevated, indicating the current market price reflects significant future pipeline success. For a company with no product revenue, that leaves limited room for clinical setbacks without meaningful price impact.
How does GLUE compare to its competitors?
Monte Rosa's molecular glue degrader platform is mechanistically distinct from the cell therapies pursued by Iovance and the protein-engineering approach of Inhibrx. All three operate in the clinical-stage small-cap biotech space, competing for capital and talent rather than direct commercial market share at this stage.
What is GLUE's market cap bracket?
Monte Rosa Therapeutics is classified as a small-cap company. Small-cap biotechs at the clinical stage typically carry higher volatility and binary risk tied to trial outcomes compared with larger, commercial-stage peers.
Who founded Monte Rosa Therapeutics?
Monte Rosa Therapeutics was incorporated in 2019. Founding context, including leadership and early backers, is publicly available through the company's official website and SEC filings.
Is GLUE a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates GLUE as Poor, with Weak scores in both Quality and Moat. Long-term quality typically requires durable competitive advantages and financial resilience — characteristics that pre-revenue clinical biotechs must still establish through successful drug development.
What is the main competitive advantage of Monte Rosa Therapeutics?
Monte Rosa's core differentiator is its QuEEN platform, which is designed to identify molecular glue degraders systematically. The approach targets proteins previously considered undruggable, potentially opening disease areas that conventional small molecules cannot address. Whether this translates into a durable moat remains to be demonstrated clinically.
What sector does GLUE belong to?
Monte Rosa Therapeutics operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. Investors can explore other [Healthcare stocks scored by UQS](/sector/healthcare) for sector-level context.
Is GLUE a growth stock or value stock?
With a Neutral Growth pillar and an Elevated Valuation rating, GLUE sits in an uncomfortable middle ground — not yet demonstrating the revenue growth typical of growth stocks, yet priced above what a value-oriented framework would typically support for a pre-revenue company.
Unlock Full GLUE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS pillar scores for GLUE
- ✓Access full financial metrics and trend data
- ✓Compare GLUE against scored biotech peers
- ✓See the complete Quality and Moat breakdown
- ✓Track Valuation changes as new data arrives
- ✓Get the full analyst-grade view in one place
Pro Analysis
GLUE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 25.7 | 10.8 | 17.0 | 43.1 | 67.2 | 0.0 | +1.8 |
| Apr 22, 2026 | 23.9 | 10.8 | 17.0 | 43.1 | 55.5 | 0.0 | -2.2 |
| Apr 2, 2026 | 26.1 | 10.8 | 17.0 | 53.8 | 55.5 | 0.0 | — |
GLUE — Pillar Breakdown
Quality
— 10.8/100 (25%)Monte Rosa Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 43.1/100 (20%)Monte Rosa Therapeutics, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 67.2/100 (15%)Monte Rosa Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Monte Rosa Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 17/100 (25%)Monte Rosa Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for GLUE.
Score Composition
Financial Data
More Stock Analysis
How is the GLUE UQS Score Calculated?
The UQS (Unified Quality Score) for Monte Rosa Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Monte Rosa Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Monte Rosa Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.